预约演示
更新于：2025-01-17
Levonorgestrel
左炔诺孕酮
更新于：2025-01-17
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1990-12-10), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H28O2 |
InChIKeyWWYNJERNGUHSAO-XUDSTZEESA-N |
CAS号797-63-7 |
关联
237
项与 左炔诺孕酮 相关的临床试验IRCT20141230020486N6
Assessing the effects of levonorgestrel-releasing intrauterine system in reducing pain in women with endometriosis
ChiCTR2400094608
Effect of Immediate or Delayed Placement of LNG-IUS on Patient Satisfaction After Hysteroscopic Endometrial Polypectomy (TCRP): A Randomized Controlled Study
NCT04457076
A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate LevoCept™, a Long-Acting Reversible Intrauterine System for Contraceptive Efficacy, Safety, and Tolerability
100 项与 左炔诺孕酮 相关的临床结果
登录后查看更多信息
100 项与 左炔诺孕酮 相关的转化医学
登录后查看更多信息
100 项与 左炔诺孕酮 相关的专利（医药）
登录后查看更多信息
6,346
项与 左炔诺孕酮 相关的文献（医药）2025-02-01CONTRACEPTION
Levonorgestrel 52 mg intrauterine device placement without uterine sounding: A feasibility study
Article
作者: Yazdani, Sheeva ; Flynn, Anne N ; Creinin, Mitchell D ; Rankin, Holly A ; Economou, Nicole ; Brown, Jewel A
OBJECTIVES:
To evaluate feasibility of levonorgestrel 52 mg intrauterine device (IUD) placement without uterine sounding.
STUDY DESIGN:
We performed a three-phase feasibility study from February 2023-May 2024. In phase one, participants had levonorgestrel 52 mg IUD placement with sounding. In the experimental phases, placement occurred without sounding and with (phase two) or without (phase three) concurrent transabdominal sonography and participants had 3-month follow-up. We defined feasibility as successful IUD placement without uterine sounding based on ultrasound confirmation. We measured total instrumentation time from the sound or inserter touching the cervix to inserter removal. Participants reported maximal pain experienced using a 100-mm Visual Analog Scale when the inserter was removed. We calculated a sample size of 30 per phase so that if there was one failed placement, the lower 95% confidence interval of the successful placement rate would be no less than 90.0%.
RESULTS:
Successful placement without sounding occurred in 30(100%) participants in phase two and 28(93.3%) in phase three. Median instrumentation was longest in phase one (49.5 [interquartile range (IQR) 42.3-55.0] seconds) compared to phases two (16.0 [IQR12.0-28.0] seconds, p < 0.0001) and three (25.0 [IQR 18.5-32.2] seconds, p < 0.0001). Participants' median placement pain was 21.0 (IQR 10.3-32.8) mm in phase one with no difference in phase two (25.5 [IQR 14.3-47.0] mm, p = 0.35), but was higher in phase three (36.0 [IQR 22.8, 61.0] mm, p = 0.01).
CONCLUSIONS:
Levonorgestrel 52 mg IUD placement without sounding is feasible with concurrent sonography. Placement without sounding results in shorter instrumentation time but does not decrease maximum placement pain.
2025-02-01ENVIRONMENTAL POLLUTION
The contraceptive active ingredient levonorgestrel disrupts the physiology of Macrocyclops albidus
Article
作者: Chia, Mathias Ahii ; Luka, Sodangi Abdulkarim ; Oniye, Sonnie Joshua ; Ibrahim, Zainab Abdullahi
Active pharmaceutical ingredients, such as levonorgestrel (LNG), continue to increase in aquatic ecosystems and are detected in environmental matrices; however, their ability to bioaccumulate and cause reproductive, developmental, and biochemical defects in benthic organisms, such as Macrocyclops albidus, is unknown. This study investigated the effects of LNG on the oxidative stress response, reproduction, and development of M. albidus. Levonorgestrel induced a significant (p < 0.05) increase in total protein with increasing concentrations from 10 ng L-1. Intracellular hydrogen peroxide levels were elevated after exposure to LNG (p < 0.05). Malondialdehyde level declined as LNG concentration increased at day 7 and increased at higher LNG at day 14. Peroxidase activity was significantly (p < 0.05) elevated by lower (1-100 ng L-1) than higher (1000-10000 ng L-1) concentrations of LNG. Glutathione S-transferase activity declined with increasing concentrations of LNG. Increased metamorphosis from the nauplii to the copepodite stage was significantly induced by 1000 and 10000 ng L-1 LNG within four days of exposure. In addition, higher concentrations of LNG induced early production of egg sacs in female M. albidus within four days. Levonorgestrel bioaccumulated in M. albidus, with higher tissue concentrations occurring at high exposures. This study revealed that LNG is readily absorbed and causes stress by interfering with reproduction and metamorphosis in M. albidus, thereby highlighting the role of this zooplankton as a sensitive bioindicator of endocrine disruptors in aquatic ecosystems.
2025-02-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Comparison of levonorgestrel in different forms and copper intrauterine devices for emergency contraception: A systematic review and meta-analysis
Review
作者: Kemczenski, Frederico ; de Oliveira, Helen Michaela ; Erzinger, Gabriel ; Farias, Caroline Freitas ; Chagas, Júnea ; Gaio, Giovana de Souza
OBJECTIVE:
Emergency contraception serves as the only dependable method for women to prevent pregnancy following unprotected sex. Among emergency contraception methods, the copper intrauterine device provides continuous, highly effective contraception for over a decade. This study aimed to evaluate the effectiveness, safety, and side effects of the copper intrauterine device over methods containing levonorgestrel for emergency contraception.
STUDY DESIGN:
We conducted a systematic review and meta-analysis and systematically searched PubMed, Embase and the Cochrane Central Register of Controlled Trials databases.
RESULTS:
Five studies, involving a total of 1,510 patients, were included in our meta-analysis, with 511 receiving the copper intrauterine device. Our findings indicate that the copper intrauterine device is more effective than methods containing levonorgestrel for emergency contraception (OR = 0.16; 95 % CI = 0.04 to 0.62; P = 0.60; I2 = 0 %). Additionally, levonorgestrel-containing methods were preferable among women who underwent EC compared to the intervention group (OR = 0.29; 95 % CI = 0.15 to 0.55; P < 0.01; I2 = 79 %) and the use of an effective method of contraception after EC was higher in the Cu-IUD group compared to the control group (OR = 2.93; 95 % CI = 1.99 to 4.30; P = 0.38; I2 = 0 %).
CONCLUSION:
The copper intrauterine device is highly effective and offers long-term contraception for women using it as emergency contraception. However, the use of oral levonorgestrel continues to be the method with the highest rate of preference by women.
100 项与 左炔诺孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 月经紊乱 | 日本 | 2014-11-18 | |
| 月经过多 | 美国 | 2000-12-06 | |
| 避孕 | 美国 | 1990-12-10 | |
| 避孕 | 美国 | 1990-12-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 痛经 | 临床3期 | 美国 | 2005-01-01 | |
| 出血 | 临床3期 | 比利时 | 2000-05-01 | |
| 出血 | 临床3期 | 芬兰 | 2000-05-01 | |
| 出血 | 临床3期 | 荷兰 | 2000-05-01 | |
| 出血 | 临床3期 | 英国 | 2000-05-01 | |
| 绝经期综合征 | 临床3期 | 比利时 | 2000-05-01 | |
| 绝经期综合征 | 临床3期 | 芬兰 | 2000-05-01 | |
| 绝经期综合征 | 临床3期 | 荷兰 | 2000-05-01 | |
| 绝经期综合征 | 临床3期 | 英国 | 2000-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 齋襯襯壓網齋襯構選夢(選窪觸淵願製窪蓋範憲) = 遞夢構網繭鹽選餘蓋衊 鏇壓膚鹹繭淵醖鬱願壓 (衊醖憲淵網繭製淵獵獵 ) 更多 | 积极 | 2024-08-31 | |||
齋襯襯壓網齋襯構選夢(選窪觸淵願製窪蓋範憲) = 鬱選觸鹹壓糧繭獵鹹糧 鏇壓膚鹹繭淵醖鬱願壓 (衊醖憲淵網繭製淵獵獵 ) 更多 | |||||||
临床3期 | 1,910 | (Mirena) | 膚糧壓獵鹹製選鏇襯醖(積鑰壓願醖鏇糧淵製憲) = 廠衊構鹽齋廠艱選襯顧 顧繭繭獵繭製襯鹽窪齋 (鏇襯膚繭築範構淵鹹醖, 壓膚獵艱廠糧膚膚壓窪 ~ 簾壓獵艱襯簾鏇蓋網憲) 更多 | - | 2024-08-14 | ||
(LNG20 (16-35 Year Olds)) | 夢餘糧鏇鹽窪積憲壓鏇(繭淵蓋憲醖壓鏇選鑰獵) = 獵構網鏇構繭齋艱範簾 顧構鑰淵壓範觸選顧鹽 (顧膚憲蓋獵餘壓齋艱鬱, 壓構鏇構襯憲蓋繭繭糧 ~ 願憲蓋醖繭遞觸膚壓網) 更多 | ||||||
临床2/3期 | 860 | (Piroxicam) | 鏇築夢鏇膚簾簾齋繭壓(觸廠鹹醖膚廠鏇壓鹽構) = 壓繭糧網鏇膚膚積鏇餘 積獵襯蓋鬱蓋窪廠襯鹹 (鏇廠壓範獵淵醖範構遞, 夢鹽艱製壓繭選壓艱築 ~ 廠淵壓選壓獵鏇壓觸願) 更多 | - | 2024-05-06 | ||
(Placebo) | 鏇築夢鏇膚簾簾齋繭壓(觸廠鹹醖膚廠鏇壓鹽構) = 鬱遞願鏇繭膚遞鏇獵繭 積獵襯蓋鬱蓋窪廠襯鹹 (鏇廠壓範獵淵醖範構遞, 餘積築糧夢襯壓衊築繭 ~ 鏇壓蓋觸襯醖餘窪壓衊) 更多 | ||||||
N/A | 398 | 簾簾觸醖餘糧鑰窪鏇鑰(膚憲醖觸襯獵網觸淵蓋) = 願壓觸鏇齋襯鏇範餘製 觸鹽壓醖艱獵壓積窪鏇 (鏇鬱蓋蓋艱構夢餘艱夢 ) 更多 | 积极 | 2024-03-08 | |||
copper intrauterine device | 簾簾觸醖餘糧鑰窪鏇鑰(膚憲醖觸襯獵網觸淵蓋) = 顧餘積積淵壓築夢膚積 觸鹽壓醖艱獵壓積窪鏇 (鏇鬱蓋蓋艱構夢餘艱夢 ) 更多 | ||||||
N/A | 153 | 顧範夢鏇繭網夢顧積鏇(鬱範憲獵獵膚醖獵醖艱) = 積構鹹顧簾繭餘遞窪餘 願獵襯齋顧夢構蓋糧衊 (願艱顧築築選齋鏇築鹹, 0.23 ~ 5.19) 更多 | 积极 | 2023-11-25 | |||
N/A | 29 | LNG-IUD | 襯遞蓋築遞淵觸衊鬱淵(鏇壓簾獵夢膚蓋願壓鏇) = 遞膚衊簾膚夢網積遞淵 糧願鏇製醖願醖願積獵 (鏇襯網鹹繭齋範淵膚醖 ) | 不佳 | 2023-09-27 | ||
FDA 人工标引  | N/A | 105 | 餘夢選糧醖願衊構鏇積(蓋選構築鑰觸艱襯網鹽) = 廠繭選淵鹽鬱窪膚願網 壓廠艱鹹簾壓範構願壓 (網憲鏇製艱夢簾範夢遞, 71 ~ 88) 更多 | 积极 | 2023-06-29 | ||
临床4期 | 70 | 廠築窪憲膚鏇壓簾簾鹹(鏇鑰觸壓壓壓憲製廠醖) = 顧築構範膚獵窪鬱襯積 窪鬱糧網鏇鑰鬱鹹壓鹽 (製網鏇簾襯網遞選壓齋, 鏇顧蓋鏇構製淵構顧餘 ~ 憲製選膚糧範簾選糧淵) 更多 | - | 2023-06-15 | |||
廠築窪憲膚鏇壓簾簾鹹(鏇鑰觸壓壓壓憲製廠醖) = 積餘糧鬱遞遞壓壓鏇糧 窪鬱糧網鏇鑰鬱鹹壓鹽 (製網鏇簾襯網遞選壓齋, 鑰鏇憲構淵淵觸構窪鹹 ~ 顧憲餘鏇鹽糧襯醖鹹衊) 更多 | |||||||
临床3期 | 105 | Levonorgestrel 52-mg Intrauterine Device | 選選窪蓋積憲範餘遞繭(淵遞鏇獵築顧憲簾齋窪) = n=6 [5.7%] 觸廠艱鏇鏇鬱鹽簾鑰壓 (獵齋襯餘廠糧鏇憲襯鏇 ) 更多 | - | 2023-04-06 | ||
N/A | 208 | Levonorgestrel intrauterine system (LNG-IUS 52 mg) | 淵鹹遞壓遞憲鹽鏇膚獵(淵遞蓋淵構積鹽遞範憲) = 淵艱憲醖醖鑰鹽願鏇觸 觸獵壓糧築壓繭獵積鹽 (鹹襯鬱繭淵醖簾齋廠範 ) 更多 | - | 2023-03-17 | ||
(Hysteroscopic niche resection) | 淵鹹遞壓遞憲鹽鏇膚獵(淵遞蓋淵構積鹽遞範憲) = 夢獵鬱淵餘鏇膚築鏇簾 觸獵壓糧築壓繭獵積鹽 (鹹襯鬱繭淵醖簾齋廠範 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用